研究者業績

苅尾 七臣

カリオ カズオミ  (Kazuomi Kario)

基本情報

所属
自治医科大学 医学部 内科学講座循環器内科学部門 教授
学位
(BLANK)

J-GLOBAL ID
200901026266273395
researchmap会員ID
1000220767

学歴

 2

論文

 293
  • Hiroyuki Mizuno, Kenji Harada, Kenta Fujimura, Kazuomi Kario
    European heart journal. Cardiovascular Imaging 2025年1月2日  
  • Keisuke Narita, Daichi Shimbo, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 47(12) 3345-3355 2024年12月  
    Previous studies have reported that blood pressure variability (BPV) is associated with the risk of cardiovascular events independent of blood pressure (BP) levels. While there is little evidence from intervention trials examining whether suppressing BPV is useful in preventing cardiovascular disease, it is suggested that detection of abnormally elevated BPV may be useful in reducing cardiovascular events adding by complementing management of appropriate BP levels. Cuffless BP devices can assess beat-to-beat BPV. Although cuffless BP monitoring devices have measurement accuracy issues that need to be resolved, this is an area of research where the evidence is accumulating rapidly, with many publications on beat-to-beat BPV over several decades. Ambulatory BP monitoring (ABPM) can assess 24-hour BPV and nocturnal dipping patterns. Day-to-day BPV and visit-to-visit BPV are assessed by self-measured BP monitoring at home and office BP measurement, respectively. 24 h, day-to-day, and visit-to-visit BPV have been reported to be associated with cardiovascular prognosis. Although there have been several studies comparing whether ABPM and self-measured BP monitoring at home is the superior measurement method of BPV, no strong evidence has been accumulated that indicates whether ABPM or self-measured home BP is superior. ABPM and self-measured BP monitoring have their own advantages and complement each other in the assessment of BPV.
  • Kazuomi Kario, Naoko Tomitani, Koki Haimoto, Keisuke Narita, Ryosuke Komi, Shinji Koba, Hidekazu Shimizu, Hiroyuki Ohbayashi, Takeshi Fujiwara, Tomoyuki Kabutoya, Hajime Kihara, Hiromitsu Sekizuka, Hiroyuki Mizuno, Yasuhisa Abe, Hajime Haimoto, Kenji Harada, Satoshi Hoshide
    Hypertension Research 2024年10月12日  
  • Masashi Kamioka, Keisuke Narita, Tomonori Watanabe, Hiroaki Watanabe, Hisaki Makimoto, Takafumi Okuyama, Ayako Yokota, Takahiro Komori, Tomoyuki Kabutoya, Yasushi Imai, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 47(10) 2800-2810 2024年10月  
    Hypertension (HTN) is one of the major risk factors for developing atrial fibrillation (AF), and it has been estimated that approximately 70% of hypertensive patients are at risk of developing AF. On the other hand, 60-80% of AF patients have HTN. These two diseases share many risk factors such as diabetes mellitus, obesity, alcohol consumption, and sleep apnea syndrome during their onset and disease progression. The mutual presence of these diseases has the potential to create a negative spiral, exacerbating each other's impact and ultimately leading to cardiovascular events such as heart failure and cerebrovascular disorders, thereby increasing mortality rates. With regard to the treatment of HTN, the variety of antihypertensive drugs and treatment options have significantly increased. Alongside the widespread adoption of antihypertensive therapy, a certain level of efficacy has been recognized in suppressing the incidence of new-onset AF. Catheter ablation is an established and effective treatment for AF. However, a notable recurrence rate persists. In recent years, management of these multiple risk factors has been recognized to be essential for suppressing AF recurrence, and recent guidelines for AF underscore the significance of proactively managing these risks before treatment. Notably, effective HTN management assumes paramount importance given its impact on the morbidity of AF patients. This review summarizes the correlation between HTN control before and after ablation and the risk of AF recurrence. The focus is on elucidating the pathophysiological background and its impact on clinical outcomes.
  • Yasuhiro Hitomi, Yasushi Imai, Masanari Kuwabara, Yusuke Oba, Tomoyuki Kabutoya, Kazuomi Kario, Hisaki Makimoto, Takahide Kohro, Eiichi Shiraki, Naoyuki Akashi, Hideo Fujita, Tetsuya Matoba, Yoshihiro Miyamoto, Arihiro Kiyosue, Kenichi Tsujita, Masaharu Nakayama, Ryozo Nagai
    International journal of cardiology. Heart & vasculature 54 101507-101507 2024年10月  
    BACKGROUND: Polypharmacy is associated with an increased risk of adverse events due to the higher number of drugs used. This is particularly notable in patients with chronic coronary syndrome (CCS), who are known to use a large number of drugs. Therefore, we investigated polypharmacy in patients with CCS, using CLIDAS, a multicenter database of patients who underwent percutaneous coronary intervention. METHOD AND RESULTS: Between 2017 and 2020, 1411 CCS patients (71.5 ± 10.5 years old; 77.3 % male) were enrolled. The relationship between cardiovascular events occurring during the median follow-up of 514 days and the number of drugs at the time of PCI was investigated. The median number of drugs prescribed was nine. Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, stroke, heart failure, transient ischemic attack, or unstable angina, occurred in 123 patients, and all-cause mortality occurred in 68 patients. For each additional drug, the adjusted hazard ratios for MACE and all-cause mortality increased by 2.069 (p = 0.003) and 1.102 (p = 0.010). The adjusted hazard ratios for MACE and all-cause mortality were significantly higher in the group using nine or more drugs compared to the group using eight or fewer drugs (1.646 and 2.253, both p < 0.001). CONCLUSION: This study showed that an increase in the number of drugs used for CCS may be associated with MACE and all-cause mortality. In patients with CCS, it might be beneficial to minimize the number of medications as much as possible, while managing comorbidities and using guideline-recommended drugs.
  • Keisuke Narita, Satoshi Hoshide, Kazuomi Kario
    American journal of hypertension 2024年7月5日  
    BACKGROUND: Previous studies with several limitations have comparatively analyzed the relationship between ambulatory blood pressure (BP) and self-measured BP and biomarkers of organ damage. This study extends this line of research by examining the relationship between ambulatory and self-measured BP and cardiac, renal, and atherosclerotic biomarkers in outpatients at cardiovascular risk. METHODS: In 1,440 practice outpatients who underwent office, ambulatory, and self-measured BP monitoring, we assessed the relationships of each BP with organ damage biomarkers including b-type natriuretic peptide (BNP), echocardiographic left ventricular mass index (LVMI), urine-albumin-creatinine ratio (UACR), and brachial-ankle pulse wave velocity (baPWV). RESULTS: In the comparison of correlation, self-measured systolic BP (SBP) was more strongly correlated to log-transformed (Ln) BNP (n=1,435; r=0.123 vs. r = -0.093, P<0.001), LVMI (n=1,278; r=0.223 vs. r=0.094, P<0.001), Ln-UACR (n=1,435; r=0.244 vs. r=0.154, P=0.010), and baPWV (n=1,360; r=0.327 vs. r=0.115, P<0.001) than daytime ambulatory SBP. In the linear regression models including office, ambulatory, and self-measured SBP, only self-measured SBP was significantly related to Ln-BNP (P=0.016) and LVMI (P<0.001). In the logistic regression models for the top quartile of LVMI, adding self-measured SBP improved the model predictability (P=0.027), but adding daytime ambulatory SBP did not. However, adding daytime ambulatory SBP improved the model predictability in the logistic model including office and self-measured SBP. CONCLUSIONS: Our study findings suggested that self-measured BP was associated with cardiac biomarkers independent of ambulatory BP.
  • Kazuomi Kario, Satoshi Hoshide, Masaki Mogi
    Hypertension Research 47(4) 833-834 2024年4月  
  • Tomonori Watanabe, Hitoshi Hachiya, Hiroaki Watanabe, Kazunori Anno, Takafumi Okuyama, Tomohiko Harunari, Ayako Yokota, Masashi Kamioka, Takahiro Komori, Yuko Torigoe-Kurosu, Hisaki Makimoto, Tomoyuki Kabutoya, Yoshifumi Kimura, Yasushi Imai, Kazuomi Kario
    Journal of arrhythmia 40(2) 363-373 2024年4月  
    BACKGROUND: The precise details of atrial activation around the triangle of Koch (ToK) remain unknown. We evaluated the relationship between the atrial-activation pattern around the ToK and success sites for slow-pathway (SP) modification ablation in slow-fast atrioventricular reentrant tachycardia (AVNRT). METHODS: Thirty patients with slow-fast AVNRT who underwent successful ablation were enrolled. Atrial activation around the ToK during sinus rhythm was investigated using ultra-high-density mapping pre-ablation. The relationships among features of atrial-activation pattern and success sites were examined. RESULTS: Of 30 patients (22 cryoablation; 8 radiofrequency ablation), 26 patients had a collision site of two wavefronts of delayed atrial activation within ToK, indicating a success site. The activation-search function of Lumipoint software, which highlights only atrial activation with a spatiotemporal consistency, showed non-highlighted area on the tricuspid-annulus side of ToK. In 23 of the patients, a spiky potential was recorded at that collision site outside the Lumipoint-highlighted area. Fifteen cryoablation patients with a success site coincident with a collision site outside the Lumipoint-highlighted area had significantly more frequent disappearances of SP after initial cryoablation (46.7% vs. 0%, p = .029), fewer cryoablations (3.7 ± 1.8 vs. 5.3 ± 1.3, p = .045), and shorter procedure times (170 ± 57 vs. 228 ± 91 min, p = .082) compared to the seven cryoablation patients without such sites. Four patients had transient AV block by ablation inside the Lumipoint-highlighted area with fractionated signals, but no patient developed permanent AV block or recurrence post-procedure (median follow-up: 375 days). CONCLUSIONS: SP modification ablation at the collision site of atrial activation of the tricuspid-annulus side along with a spiky potential could provide a better outcome.
  • Tomonori Watanabe, Satoshi Hoshide, Hitoshi Hachiya, Yoshiyuki Yumita, Masafumi Sato, Tadayuki Mitama, Takafumi Okuyama, Hiroaki Watanabe, Ayako Yokota, Masashi Kamioka, Takahiro Komori, Hisaki Makimoto, Tomoyuki Kabutoya, Yasushi Imai, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 2024年3月26日  
    Lack of the typical nocturnal blood pressure (BP) fall, i.e non-dipper, has been known as a cardiovascular risk. However, the influence of non-dipper on atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) has been unclear. We investigated the clinical impact of non-dipping as evaluated by 24-hour ambulatory BP monitoring on the long-term outcome of AF recurrence post-PVI in 76 AF patients with a history of increased BP. The PVI procedure was successful in all 76 patients (mean age, 66±9years; antihypertensive medication, 89%; non-paroxysmal AF, 24%). Twenty patients had AF recurrence during a median follow-up of 1138 days. There was no difference in BP levels between the AF recurrence and non-recurrence groups (average 24 h systolic BP:126 ± 17 vs.125 ± 14 mmHg; P = 0.84). On the other hand, the patients with non-dipper had a higher AF recurrence than those with dipper (38.9% vs.15.0%; P = 0.018). In Cox hazard analysis adjusted by age, non-paroxysmal AF and average 24-hr systolic BP level, the non-dipper was an independent predictor of AF recurrence (HR 2.78 [95%CI:1.05-7.34], P = 0.039). Non-dipper patients had a larger left atrial (LA) volume index than the dipper patients (45.9 ± 17.3 vs.38.3 ± 10.2 ml/m2, P = 0.037). Among the 58 patients who underwent high-density voltage mapping in LA, 11 patients had a low-voltage area (LVA) defined as an area with a bipolar voltage < 0.5 mV. However, there was no association of LVA with non-dipper or dipper (22.2% vs.16.1%, P = 0.555). Non-dipper is an independent predictor of AF recurrence post-PVI. Management of abnormal diurnal BP variation post-PVI may be important.
  • Masaki Mogi, Yasuhito Ikegawa, Shunsuke Haga, Satoshi Hoshide, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 2024年3月15日  
    Hypertension, a disease whose prevalence increases with age, induces pathological conditions of ischemic vascular disorders such as cerebral infarction and myocardial infarction due to accelerated arteriosclerosis and circulatory insufficiency of small arteries and sometimes causes hemorrhagic conditions such as cerebral hemorrhage and ruptured aortic aneurysm. On the other hand, as it is said that aging starts with the blood vessels, impaired blood flow associated with vascular aging is the basis for the development of many pathological conditions, and ischemic changes in target organs associated with vascular disorders result in tissue dysfunction and degeneration, inducing organ hypofunction and dysfunction. Therefore, we hypothesized that hypertension is associated with all age-related vascular diseases, and attempted to review the relationship between hypertension and diseases for which a relationship has not been previously well reported. Following our review, we hope that a collaborative effort to unravel age-related diseases from the perspective of hypertension will be undertaken together with experts in various specialties regarding the relationship of hypertension to all pathological conditions.
  • Kazuomi Kario, Ayako Okura, Satoshi Hoshide, Masaki Mogi
    Hypertension research : official journal of the Japanese Society of Hypertension 2024年3月5日  
    Thirty-year % increase of adults with hypertension in the European/ Americas and South-East Asia/ Western Pacific (WHO region). Create using the data from: World Health Organization. Global report on hypertension: the race against a silent killer. Geneva, Switzerland: 2023.
  • 成田 圭佑, 星出 聡, 苅尾 七臣
    自治医科大学紀要 46 83-84 2024年3月  
  • 弓田 馨之, 渡部 智紀, 星出 聡, 渡邉 裕昭, 上岡 正志, 蜂谷 仁, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 ECC-3 2024年3月  
  • 横田 彩子, 甲谷 友幸, 三玉 唯由季, 奥山 貴文, 渡邉 裕昭, 上岡 正志, 小森 孝洋, 渡部 智紀, 牧元 久樹, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ019-3 2024年3月  
  • 渡邉 裕昭, 牧元 久樹, 興梠 貴英, 菅沼 雅徳, 岡谷 貴之, 奥山 貴文, 横田 彩子, 上岡 正志, 小森 孝洋, 渡部 智紀, 甲谷 友幸, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ047-4 2024年3月  
  • 上岡 正志, 渡部 智紀, 渡邉 裕昭, 牧元 久樹, 奥山 貴文, 横田 彩子, 小森 孝洋, 甲谷 友幸, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ071-5 2024年3月  
  • 渡部 智紀, 奥山 貴文, 渡邉 裕昭, 上岡 正志, 牧元 久樹, 三玉 唯由季, 佐藤 雅史, 横田 彩子, 小森 孝洋, 甲谷 友幸, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ092-3 2024年3月  
  • 三玉 唯由季, 甲谷 友幸, 奥山 貴文, 渡邉 裕昭, 横田 彩子, 上岡 正志, 渡部 智紀, 小森 孝洋, 牧元 久樹, 今井 靖, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ116-5 2024年3月  
  • 石山 裕介, 大場 祐輔, 牧元 久樹, 菅沼 雅徳, 岡谷 貴之, 興梠 貴英, 苅尾 七臣
    日本循環器学会学術集会抄録集 88回 PJ047-3 2024年3月  
  • Kazuomi Kario, Satoshi Hoshide, Masaki Mogi
    Hypertension Research 47(2) 251-252 2024年2月  
  • Satoshi Hoshide, Masaki Mogi, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 47(2) 253-254 2024年2月  
  • 今井 靖, 苅尾 七臣
    日本臨床薬理学会学術総会抄録集 44回 3-3 2024年1月  
  • 甲谷 友幸, 関 満, 柏原 香菜, 藤村 研太, 今井 靖, 苅尾 七臣, 古井 貞浩, 鈴木 峻, 岡 健介, 松原 大輔, 佐藤 智幸, 金子 政弘, 友保 貴博, 岡 徳彦
    日本成人先天性心疾患学会雑誌 13(1) 161-161 2024年1月  
  • 藤村 研太, 甲谷 友幸, 関 満, 久保田 香菜, 今井 靖, 苅尾 七臣, 古井 貞浩, 鈴木 峻, 岡 健介, 松原 大輔, 佐藤 智幸, 金子 政弘, 友保 貴博, 岡 徳彦
    日本成人先天性心疾患学会雑誌 13(1) 173-173 2024年1月  
  • Keisuke Narita, Zihan Yuan, Nobuhiko Yasui, Satoshi Hoshide, Kazuomi Kario
    JACC. Advances 3(1) 100737-100737 2024年1月  
    BACKGROUND: A simple ambulatory measure of cardiac function could be helpful for monitoring heart failure patients. OBJECTIVES: The purpose of this paper was to determine whether a novel pulse waveform analysis using data obtained by our developed multisensor-ambulatory blood pressure monitoring (ABPM) device, the 'Sf/Am' ratio, is associated with echocardiographic left ventricular ejection fraction (LVEF). METHODS: Multisensor-ABPM was conducted twice at baseline in 20 heart failure (HF) patients with HF-reduced LVEF or HF-preserved LVEF (median age 66 years, male 65%) and over a 6- to 12-month follow-up after patient-tailored treatment. We assessed the changes in the pulse waveform index Sf/Am and LVEF that occurred between the baseline and follow-up. The Sf/Am consists of the area of the ejection part in the square forward wave (Sf) and the amplitude of the measured wave (Am). We divided the patients into the recovered (n = 11) and not-recovered (n = 9) groups defined by a ≥10% increase in LVEF. RESULTS: Although the ambulatory BP levels and variabilities did not change in either group, the Sf/Am increased significantly in the recovered group (baseline 21.4 ± 4.5; follow-up, 25.6 ± 3.7, P = 0.004). The not-recovered group showed no difference between the baseline and follow-up. The follow-up/baseline Sf/Am ratio was significantly associated with the LVEF ratio (r = 0.469, P = 0.037). The Sf/Am was significantly correlated with the LVEF in overall measurements (n = 40, r = 0.491, P = 0.001). CONCLUSIONS: These results demonstrated that a novel noninvasive pulse waveform index, the Sf/Am measured by multisensor-ABPM is associated with LVEF. The Sf/Am may be useful for estimating cardiac function.
  • Hiroyuki Mizuno, Eunhee Choi, Kazuomi Kario, Paul Muntner, Chloe L. Fang, Justin Liu, Dona N. Sangapalaarachchi, Michael Lam, Yuichiro Yano, Joseph E. Schwartz, Daichi Shimbo
    Journal of the American Heart Association 2023年12月19日  査読有り
  • Kazuomi Kario, Naoko Tomitani, Satoshi Hoshide, Masafumi Nishizawa, Tetsuro Yoshida, Tomoyuki Kabutoya, Takeshi Fujiwara, Hiroyuki Mizuno
    Journal of the American Heart Association 2023年12月  査読有り
  • Kazuomi Kario, Satoshi Hoshide, Masaki Mogi
    Hypertension research : official journal of the Japanese Society of Hypertension 46(12) 2557-2560 2023年12月  
  • Keisuke Narita, Satoshi Hoshide, Kazuomi Kario
    Journal of clinical medicine 12(23) 2023年11月22日  
    Although various guidelines for cardiovascular disease prevention have been established, the optimal drug therapy is often not implemented due to poor medication adherence and the clinical inertia of healthcare practitioners. Polypill strategies are one solution to this problem. Previous studies have established the usefulness of polypills, i.e., combination tablets including three or more medications, for the prevention of cardiovascular disease. For this purpose, the polypills generally contain an antiplatelet medication, an antihypertensive medication, and a statin. For the specific management of hypertension, combination therapy including more than two classes of antihypertensive medications is recommended by most international guidelines. Combination tablets including two classes of antihypertensive medications, such as renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin receptor blockers [ARBs]) and Ca-channel blockers or thiazide diuretics, have been reported to be useful for cardiovascular disease prevention and lowering blood pressure (BP) levels. The use of RAS inhibitors is recommended for a wide range of complications, including diabetes, chronic heart failure, and chronic kidney disease. The combination of an RAS inhibitor and diuretic or Ca-channel blocker is thus recommended for the management of hypertension. Finally, we expect that novel medications such as angiotensin receptor neprilysin inhibitors (ARNIs) and sodium glucose cotransporter 2 inhibitors (SGLT2i), which have a more diverse range of effects in hypertension, heart failure, or diabetes, may be a solution to the problem of polypharmacy. Evidence is accumulating on the benefits of polypill strategies in cardiovascular disease prevention. Combination tablets are also effective for the treatment of hypertension.
  • Kazuomi Kario, Naoko Tomitani, Satoshi Hoshide, Masafumi Nishizawa, Tetsuro Yoshida, Tomoyuki Kabutoya, Takeshi Fujiwara, Hiroyuki Mizuno, Yukie Okawara, Hiroshi Kanegae
    Hypertension 2023年11月  査読有り
  • 成田 圭佑, 苅尾 七臣
    Heart View 27(12) 70-75 2023年11月  
    <文献概要>高血圧は心血管疾患の危険因子の一つであり,これまでの介入試験の結果,降圧管理が心血管疾患の発症予防に有用であることが明らかとなっている。本稿では日本の高血圧治療ガイドライン2019に準拠した標準的な降圧治療に加え,近年,注目が高まっている夜間血圧や治療抵抗性高血圧,日本で使用可能となっている新規薬剤についても述べる。
  • David E. Kandzari, Raymond R. Townsend, Kazuomi Kario, Felix Mahfoud, Michael A. Weber, Roland E. Schmieder, Stuart Pocock, Konstantinos Tsioufis, Dimitrios Konstantinidis, James Choi, Cara East, Lucas Lauder, Debbie L. Cohen, Taisei Kobayashi, Axel Schmid, David P. Lee, Adrian Ma, Joachim Weil, Tolga Agdirlioglu, Markus P. Schlaich, Sharad Shetty, Chandan M. Devireddy, Janice Lea, Jiro Aoki, Andrew S.P. Sharp, Richard Anderson, Martin Fahy, Vanessa DeBruin, Sandeep Brar, Michael Böhm, Yale Wang, Desmond Jay, Brent McLaurin, Carl Lomboy, Suhail Allaqaband, Fuad Jan, Bharat Gummadi, Marc Litt, Fidel Garcia, Jasvindar Singh, Angela Brown, James Choi, Ashley Paul, Andrew Sharp, James Coulson, Aravinda Nanjundappa, Ganpat Thakker, James Campbell, Benjamin Honton, Bruno Farah, Manesh Patel, Antonio Gutierrez, Crystal Tyson, Laura Svetkey, Marat Fudim, Neha Pagidipati, Schuyler Jones, Sreekanth Vemulapalli, Chandan Devireddy, Ambar Kulshreshtha, Bryan Wells, Janice Lea, Bryan Batson, Robert Wilkins, Faisal Sharif, Abdullahi Mohamed Khair, Abhishek Wilson Pallippattu, Aishah Matar Alhmoudi, Brian Gaffney, Christian Cawley, Colin Gorry, Hanan Hamed, Jennifer Carron, John Birrane, Liesbeth Rosseel, Mattia Lunardi, Michael Cronin, Myles McKittrick, Naeif Almagal, Noman Khalid, Qussai Shehahd, Shirjeel Shahzad, Simone Fezzi, Stanislav Tyulkin, Xavier Armario Bel, Sanjit Jolly, Gordon Yip, Jon-David Schwalm, Michael Tsang, Shamir Mehta, Philipp C. Lurz, Christian Binner, Danilo Obradovic, Florian Fahr, Ines Richter, Johannes Rotta detto Loria, Karl Fengler, Karl-Philipp Rommel, Mateo Marin Cuartas, Matthias Lerche, Philipp Hartung, Phillip Münch, Robert Höllriegel, Silke John, Satoru Otsuji, Hirofumi Kusumoto, Hiroto Tamaru, Kasumi Ishibuchi, Katsuyuki Hasegawa, Ken Sugimoto, Mikio Kakishita, Rui Ishii, Shin Takiuchi, Shingo Yasuda, Sho Nakabayashi, Wataru Yamamoto, Yorihiko Higashino, Yuji Shimatani, Yusuke Taniguchi, Konstantinos Tsioufis, Alexandros Kasiakogias, Dimitris Konstantinidis, Eirini Andrikou, Konstantinos Konstantinou, Kyriakos Dimitriadis, Theodoros Kalos, Debbie Cohen, Garvey Rene, Jordana Cohen, Maria Bonanni, Matthew Denker, Rasi Wickramisinghe, Robert Wilensky, Tai Kobayashi, Venkatesh Anjan, Yonghong Huan, Walter Herbert Haught, Joshua Krasnow, Alejandro Vasquez, Carl Gessler, Christopher Roth, David Drenning, Enrique Velasquez, George Soliman, James Murphy, Kaushik Jain, Michael Butler, Mihir Kanitkar, Phillip Laney, Ross Hunter, Shi-Chi Cheng, Thomas Wright, Walter Herbert Haught, Neil Chapman, Ahran Arnold, Alexandra Nowbar, Azara Janmohamed, Ben Corden, Christopher Cook, Christopher Rajkumar, Daniel Keene, David Thompson, Henry Seligman, James Howard, Justin Davies, Mark Sweeney, Matthew Shun-Shin, Michael Foley, Nicholas Quaife, Rasha Al-Lamee, Savvas Hadjiphilippou, Sayan Sen, Yousif Ahmad, Kazuomi Kario, Hayato Shimizu, Hirotaka Waki, Keisuke Narita, Masahisa Shimpo, Satoshi Hoshide, Takahiro Komori, Yukako Ogoyama, Yukiyo Ogata, Yusuke Oba, Mohanned Bisharat, Anton Lishmanov, Mohanned Bisharat, Travis Jeffords, Magdi Ghali, Beth Chia, Rachel Onsrud, Randolph Rough, Jiro Aoki, Daijiro Tomii, Fumiko Mori, Hosei Kikushima, Kai Ninomiya, Kazuyuki Yahagi, Kengo Tanabe, Kosuke Nakamura, Kota Komiyama, Masaaki Nakase, Masahiko Asami, Naoto Setoguchi, Tetsu Tanaka, Yu Horiuchi, Yusuke Watanabe, Dmitriy Feldman, Geoffrey Bergman, Ines Sherifi, Luke Kim, Nivee Amin, Robert Minutello, S. Chiu Wong, Stephen McCullough, Richard D'Souza, Andrew Sharp, Hibba Kurdi, Richard D'Souza, Sarah Statton, Tony Watkinson, Barry Bertolet, Amit Gupta, Benjamin Blossom, Chris Bell, Douglas Hill, Francisco Sierra, James Johnson, John Estess, Joseph Adams, Katie McDuffie, Lee Ferguson, Nelson Little, Richard Dane Ballard, Roger Williams, Wanda Ikeda, William Calhoun, William Carroll, Avneet Singh, Benjamin Hirsh, Perwaiz Meraj, Rajiv Jauhar, Harsh Golwala, Jose Rueda, Kellie Graham, Ramsey Al-Hakim, Robert Rope, David Kandzari, Dariush Bahrami, Denise Reedus, Shukri David, Iram Rehman, Khalid Zakaria, Nishit Choksi, Samer Kazziha, Sarwan Kumar, Souheil Saba, Susan Steigerwalt, Yassir Sirajeldin, Omar Hyder, Herbert Aronow, Andrea Connors, Douglas Shemin, Clare Bent, Terry Levy, Vivek Kodoth, Markus Schlaich, Marcio Kiuchi, Revathy Carnagarin, Sharad Shetty, Sabino Torre, Howard Levitt, Lin Chen, Sarah Fan, Sergio Waxman, Wendy Porr, George Mangos, Brendan Smyth, Cathie Lane, Mark Sader, Kirit Kumar Patel, Anjani Rao, Brett Milford, Guneet Ahluwalia, Jaqueline Sennott, Justin Field, Nihar Jena, Stacy Loree, John Graham, Abdul Al-Hesayen, Akshay Bagai, Junya Shite, Amane Kozuki, Atsushi Suzuki, Eri Masuko, Fumitaka Soga, Hiroyuki Asada, Hiroyuki Shibata, Ryoji Nagoshi, Ryudo Fujiwara, Shokan Kyo, Tomohiro Miyata, Yoichi Kijima, Joachim Weil, Lena Griesinger, Lukas Hafer, Rene-Alexander Starick, Sebastian Keil, Tolga Agdirlioglu, Udo Desch, Shigeru Saito, Eiji Koyama, Futoshi Yamanaka, Hiroaki Yokoyama, Kazuki Tobita, Koki Shishido, Masashi Yamaguchi, Masato Murakami, Noriaki Moriyama, Saeko Takahashi, Shingo Mizuno, Shohei Yokota, Takahiro Hayashi, Takashi Yamada, Tamiharu Yamagishi, Yoichi Sugiyama, Yuka Mashimo, Yusuke Tamaki, Yutaka Tanaka, David Lee, Adrian Ma, Alan Yeung, Thomas Noel, Ernesto Umana, John Katopodis, William Dixon, Tony Walton, Adam Rischin, Adrian Chee, Alexandra Leaney, Himavan Fernando, Ingrid Hopper, Jason Bloom, Jessica Fairley, Julia Stehli, Julian Segan, Meenal Sharma, Melissa Fitzgerald, Michelle Papandony, Naomi Whyler, Samer Noaman, Shazeea Ali, Brian Jefferson, David Reyes, Thomas Johnston, Michael Böhm, Alexander Höfling, Ann-Kathrin Berger, Bodo Cremers, Dominic Millenaar, Felix Mahfoud, Ina Zivanovic, Jelena Lucic, Juliane Dederer, Lucas Lauder, Patrick Fischer, Saarraangan Kulenthiran, Sebastian Ewen, Yvonne Bewarder, Roland Schmieder, Agnes Bosch, Axel Schmid, Christian Ott, Dennis Kannenkeril, Ertan Akarca, Iris Kistner, Julie Kolwelter, Karl Bihlmaier, Kristina Striepe, Marina Karg, Merve Günes-Altan, Stefanie Sofia Anna Friedrich, Susanne Jung, Thomas Dienemann, Antonios Ziakas, Antonios Kouparanis, Areti Pagiantza, Emmanouela Peteinidou, Matthaios Didagelos, Polykarpos Akis Psochias, Mehdi Shishehbor, Ashley Meade, Elena Linetsky, Monique Robinson, John Kotter, Khaled Ziada, John Kotter, William Bachinsky, Alex Garton, Jason Stuck, Vasilios Papademetriou, Annise Chung, Ping Li, Sameer Nagpal, Michael Remetz, Samit Shah, Shannon Lynch
    Journal of the American College of Cardiology 82(19) 1809-1823 2023年11月  
  • Masaki Mogi, Satoshi Hoshide, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(11) 2445-2446 2023年11月  
  • Satoshi Hoshide, Masaki Mogi, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(10) 2262-2263 2023年10月  
  • Yusuke Oba, Hiroshi Funayama, Masafumi Sato, Hisaya Kobayashi, Kenji Harada, Mamoru Arakawa, Koji Kawahito, Kazuomi Kario
    European Heart Journal - Imaging Methods and Practice 1(2) 2023年9月8日  
  • Keisuke Narita, Satoshi Hoshide, Kazuomi Kario
    Hypertension (Dallas, Tex. : 1979) 2023年9月6日  
    BACKGROUND: Although blood pressure variability (BPV) is reported to be associated with cardiovascular prognoses, it has not been established whether ambulatory BPV ([ABPV], ie, short-term 24-hour BPV) or home BPV ([HBPV], day-to-day BPV) is a superior clinical marker. METHODS: We analyzed the associations of ABPV and HBPV with cardiovascular prognoses and biomarkers in 1314 hypertensive outpatients who underwent both home and ambulatory BP measurements in the J-HOP study (Japan Morning-Surge Home Blood Pressure). BPV was evaluated by the SD, coefficient of variation, and average real variability of the patients' 24-hour ambulatory and home systolic BP values. RESULTS: During the median 7.0-year follow-up, 109 cardiovascular events occurred. All SD, coefficient of variation, and average real variability values of the HBPV were significantly associated with cardiovascular risk even after adjusting by average 24-hour ambulatory systolic BP and each ABPV value: 1 SD of hazard ratio (95% CI) for the SD, 1.36 (1.14-1.63); coefficient of variation, 1.38 (1.16-1.66); and average real variability 1.29 (1.10-1.51) of HBPV. The ABPV parameters did not exhibit comparable relationships. The cardiovascular risk spline curves showed a trend toward increased risks with increasing HBPV parameters. There were no differences between ABPV and HBPV in the relationships with B-type natriuretic peptide and the urine albumin-creatine ratio. CONCLUSIONS: In this comparative analysis of ambulatory and home BP monitoring values in individuals with hypertension, ABPV was not significantly associated with cardiovascular prognosis adjusted by average BP level, and HBPV was suggested to have modest superiority in predicting cardiovascular prognosis compared with ABPV.
  • 朝日 善治, 甲谷 友幸, 奥山 貴文, 渡邉 裕昭, 上岡 正志, 渡部 智紀, 小森 孝洋, 牧元 久樹, 今井 靖, 苅尾 七臣
    日本内科学会関東地方会 689回 29-29 2023年9月  
  • 黒木 安優香, 森田 愛理, 大場 祐輔, 和地 純佳, 石山 裕介, 清水 勇人, 船山 大, 苅尾 七臣
    日本内科学会関東地方会 689回 29-29 2023年9月  
  • 鈴木 規泰, 鈴木 悠介, 大場 祐輔, 船山 大, 苅尾 七臣
    日本心臓病学会学術集会抄録 71回 C-5 2023年9月  
  • Masashi Kamioka, Hisaki Makimoto, Tomonori Watanabe, Hiroaki Watanabe, Takafumi Okuyama, Takashi Kaneshiro, Naoko Hijioka, Ayako Yokota, Takahiro Komori, Tomoyuki Kabutoya, Yasushi Imai, Kazuomi Kario
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 25(9) 2023年8月2日  
    AIMS: The relationship between local unipolar voltage (UV) in the pulmonary vein (PV)-ostia and left atrial wall thickness (LAWT) and the utility of these parameters as indices of outcome after atrial fibrillation (AF) ablation remain unclear. METHODS AND RESULTS: Two-hundred seventy-two AF patients who underwent AF ablation were enrolled. Unipolar voltage of PV-ostia was measured using a CARTO system, and LAWT was measured using computed tomography. The primary endpoint was atrial tachyarrhythmia (ATA) recurrence including AF. The ATA recurrence was documented in 74 patients (ATA-Rec group). The UV and LAWT of the bilateral superior PV roof to posterior and around the right-inferior PV in the ATA-Rec group were significantly greater than in patients without ATA recurrence (ATA-Free group) (P < 0.001). The UV had a strong positive correlation with LAWT (R2 = 0.446, P < 0.001). The UV 2.7 mV and the corresponding LAWT 1.6 mm were determined as the cut-off values for ATA recurrence (P < 0.001, respectively). Multisite LA high UV (HUV, ≥4 areas of >2.7 mV) or multisite LA wall thickening (≥5 areas of >1.6 mm), defined as LA hypertrophy (LAH), was related to higher ATA recurrence. Among 92 LAH patients, 66 had HUV (LAH-HUV) and the remaining 26 had low UV (LAH-LUV), characterized by history of non-paroxysmal AF and heart failure, reduced LV ejection fraction, or enlarged LA. In addition, LAH-LUV showed the worst ablation outcome, followed by LAH-HUV and No LAH (log-rank P < 0.001). CONCLUSION: Combining UV and LAWT enables us to stratify recurrence risk and suggest a tailored ablation strategy according to LA tissue properties.
  • Ayako Yokota, Tomoyuki Kabutoya, Tadayuki Mitama, Takafumi Okuyama, Hiroaki Watanabe, Masashi Kamioka, Tomonori Watanabe, Takahiro Komori, Yasushi Imai, Kazuomi Kario
    Journal of arrhythmia 39(4) 574-579 2023年8月  
    BACKGROUND: While most VVI pacemakers in bradycardic patients are set to a low limit of 60/min, the optimal lower limit rate for VVI pacemakers in atrial fibrillation has not been established. Although an increase in heart rate within the normal range in the setting of a VVI pacemaker might be expected to lead to an increase in cardiac output with the shortening of the diastolic time, the changes in cardiac output at different pacemaker settings have not been fully clarified. METHODS: We included 11 patients with bradycardic atrial fibrillation who had VVI pacemakers implanted. Stroke volume was measured using the electrical cardiometry method (AESCULONⓇ mini; Osypka Medical) without pacing and at ventricular pacings of 60, 70, 80, and 90/min. RESULTS: Stroke volume decreased stepwise at ventricular pacing rates of 60, 70, 80, and 90/min (63.6 ± 11.2, 61.9 ± 10.6, 59.3 ± 12.2, and 57.5 ± 12.2 mL, p < .001), but cardiac output increased (3.81 ± 0.67, 4.33 ± 0.74, 4.74 ± 0.97, and 5.17 ± 1.09 L/min, p < .001). The rate of increase in cardiac output at a pacing rate of 70/min compared to 60/min correlated with left ventricular end-systolic volume (r = 0.711, p = .014). CONCLUSIONS: Cardiac output increased at a pacing rate of 70 compared to 60 in bradycardic atrial fibrillation patients, and the rate of increase in cardiac output was greater in those with larger left ventricular end-systolic volume.
  • Masaki Mogi, Satoshi Hoshide, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(8) 1827-1828 2023年8月  
  • Kazuomi Kario, Naoyuki Hasebe, Ken Okumura, Takeshi Yamashita, Masaharu Akao, Hirotsugu Atarashi, Takanori Ikeda, Yukihiro Koretsune, Wataru Shimizu, Shinya Suzuki, Hiroyuki Tsutsui, Kazunori Toyoda, Atsushi Hirayama, Masahiro Yasaka, Takenori Yamaguchi, Satoshi Teramukai, Tetsuya Kimura, Yoshiyuki Morishima, Atsushi Takita, Hiroshi Inoue
    Hypertension research : official journal of the Japanese Society of Hypertension 2023年7月11日  
    The benefits of direct oral anticoagulants (DOACs) and warfarin in elderly Japanese patients with non-valvular atrial fibrillation (NVAF) and high home systolic blood pressure (H-SBP) are unclear. This sub-cohort study of the ANAFIE Registry estimated the incidence of clinical outcomes in patients receiving anticoagulant therapy (warfarin and DOACs) stratified by H-SBP levels (<125 mmHg, ≥125-<135 mmHg, ≥135-<145 mmHg and ≥145 mmHg). Of the overall ANAFIE population, 4933 patients who underwent home blood pressure (H-BP) measurements were analyzed; 93% received OACs (DOACs: 3494, 70.8%; warfarin: 1092, 22.1%). In the warfarin group, at <125 mmHg and ≥145 mmHg, the respective incidence rates (per 100 person-years) were 1.91 and 5.89 for net cardiovascular outcome (a composite of stroke/systemic embolic events (SEE) and major bleeding), 1.31 and 3.39 for stroke/SEE, 0.59 and 3.91 for major bleeding, 0.59 and 3.43 for intracranial hemorrhage (ICH), and 4.01 and 6.24 for all-cause death. Corresponding incidence rates in the DOACs group were 1.64 and 2.65, 1.00 and 1.88, 0.78 and 1.69, 0.55 and 1.31, and 3.43 and 3.51. In warfarin-treated patients, the incidence rates of net cardiovascular outcome, stroke/SEE, major bleeding, and ICH were significantly increased at H-SBP ≥ 145 mmHg versus <125 mmHg. In the DOAC group, although there was no significant difference between H-SBP < 125 mmHg and ≥145 mmHg, the incidence rates of these events tended to increase at ≥145 mmHg. These results suggest that strict BP control guided by H-BP is required in elderly NVAF patients receiving anticoagulant therapy.
  • Keisuke Narita, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(7) 1710-1711 2023年7月  
  • Satoshi Hoshide, Masaki Mogi, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(7) 1636-1637 2023年7月  
  • 成田 圭佑, 苅尾 七臣
    Heart View 27(6) 502-507 2023年6月  
    <文献概要>Point 1 高血圧・血圧サージは腎機能障害を含む臓器障害を引き起こし,これらの臓器障害は血圧コントロールを悪化させ,心血管疾患の発症へとつながる。2 腎機能障害を合併している高血圧患者では,夜間高血圧を呈している場合がある。3 食塩感受性,交感神経活性の過度な亢進と高血圧の病態に関連がある。
  • Kazuomi Kario, Satoshi Hoshide, Masaki Mogi
    Hypertension research : official journal of the Japanese Society of Hypertension 46(6) 1357-1362 2023年6月  
  • Kazuomi Kario, Satoshi Hoshide, Masaki Mogi
    Hypertension research : official journal of the Japanese Society of Hypertension 2023年5月15日  
  • Masaki Mogi, Satoshi Hoshide, Kazuomi Kario
    Hypertension research : official journal of the Japanese Society of Hypertension 46(5) 1071-1072 2023年5月  

MISC

 224
  • 石井 正将, 大塚 康弘, 池邉 壮, 中村 太志, 辻田 賢一, 藤田 英雄, 的場 哲哉, 興梠 貴英, 大場 祐輔, 甲谷 友幸, 苅尾 七臣, 清末 有宏, 水野 由子, 中山 雅晴, 宮本 恵宏, 佐藤 寿彦, 永井 良三
    日本循環器学会学術集会抄録集 88回 PJ122-2 2024年3月  
  • Masaki Mogi, Yasuhito Ikegawa, Shunsuke Haga, Satoshi Hoshide, Kazuomi Kario
    Hypertension Research 2024年  
    Hypertension, a disease whose prevalence increases with age, induces pathological conditions of ischemic vascular disorders such as cerebral infarction and myocardial infarction due to accelerated arteriosclerosis and circulatory insufficiency of small arteries and sometimes causes hemorrhagic conditions such as cerebral hemorrhage and ruptured aortic aneurysm. On the other hand, as it is said that aging starts with the blood vessels, impaired blood flow associated with vascular aging is the basis for the development of many pathological conditions, and ischemic changes in target organs associated with vascular disorders result in tissue dysfunction and degeneration, inducing organ hypofunction and dysfunction. Therefore, we hypothesized that hypertension is associated with all age-related vascular diseases, and attempted to review the relationship between hypertension and diseases for which a relationship has not been previously well reported. Following our review, we hope that a collaborative effort to unravel age-related diseases from the perspective of hypertension will be undertaken together with experts in various specialties regarding the relationship of hypertension to all pathological conditions. (Figure presented.).
  • 人見泰弘, 今井靖, 桑原政成, 牧元久樹, 興梠貴英, 相澤健一, 大場祐輔, 甲谷友幸, 苅尾七臣, 的場哲哉, 藤田英雄, 永井良三
    日本臨床薬理学会学術総会抄録集(Web) 44th 2023年  
  • Michiaki Nagai, Takeshi Fujiwara, Kazuomi Kario
    Journal of Clinical Hypertension 23(9) 1681-1683 2021年9月1日  
  • Michiaki Nagai, Kazuomi Kario
    Journal of Clinical Hypertension 23(8) 1526-1528 2021年8月1日  

共同研究・競争的資金等の研究課題

 28